

Concurrent Chemoradiation in Nasopharyngeal Cancer

Yaowalak Chansilpa, M.D.

Janjira Petsuksiri, M.D.

Faculty of Medicine, Siriraj Hospital,
Thailand

Eligibility

- Patients characteristics
- Chemotherapy : Cisplatin 30 mg/m² weekly
- Radiation techniques and dose
- Compliance
- Toxicity
- Result

Patient characteristics

- 2 cases
- Age 44 - 59
- PS gr 0-1
- Pathology :
 - Type 3 Undifferentiated : Both
- Staging of disease :
 - T 2 N 3a M 0 (Stage IV B) : Both

Concurrent chemotherapy

- Cisplatin 30 mg/ m² weekly for 6 cycles
- Ondansetron 8 mg iv for premedication

Radiation techniques

■ External radiation



- Two lateral neck

Dose 46 Gy then off cord

Boost primary tumor and enlarged node
to 70 Gy

- Anterior Split

Dose 50 Gy



Compliance

- Complete for 6 cycles : Both
- Interruption of RT and Chemo in week 5 due to grade 3 mucositis : Both
- Treatment time : 55 – 56 days

Toxicities

	No 1	No 2
Hematologic		
WBC	0	0
RBC	0	0
Neutrophil	0	0
Platelet	0	0

Toxicities

	No. 1	No. 2
Skin	2	2
Mucositis	3	3
Renal	0	0
Weight loss	2	1
Fatigue	2	2
N / V	1	1

Result of treatment

- Just finished the treatment for 1 month
: Partial response

Conclusion

- Concurrent chemoradiation treatment for 30 mg/m² cisplatin weekly is tolerable in both patients. (6 cycles)
- Maximum grade 3 mucositis for both patients : Interruption of treatment for 1 week (at 5th week of treatment)

Remind for last year (2002)

Concurrent chemoradiation in nasopharyngeal cancer

■ Concurrent

- cisplatin (100mg/m² q 3 wks)

■ Adjuvant

- cisplatin (80 mg/m²) d1

- + 5FU (1000mg/m²) d1-4

- 9 patients
- Age 32-62 yrs
- staging
> or = T 3 or N 1 lesion
- Patho: SCC
: undiff. CA

Compliance during treatment

■ Concurrent Period

2 cycles : 88.89 % (8/9)

1 cycle : 11.11% (1/9) (BM hypoplasia)

■ Adjuvant Period

3 cycles : 33.33 % (3/9)

2 cycles : 11.11 % (1/9)

1 cycles : 22.22% (2/9) (lost)

0 cycles : 33.33% (3/9) (2 lost, 1 BM hypoplasia)

Concurrent period (9pts)

Toxicity	Gr 0-1	Gr 2	Gr 3	Gr4
Hematological				
-anemia	6/9	3/9	0	0
-neutropenia	7/9	1/9	0/9	1/9
-thrombo cytopenia	gr 0 all			
GI				
- N/V	6/9	3/9	0/9	0/9
-diarrhea	gr 0 all			
Renal	9/9	0/9	0/9	0/9
Mucositis	in wk 2		in wk 4-5	

Adjuvant period (6pts)

Toxicity	Gr 0-1	Gr 2	Gr 3	Gr4
Hematological				
-anemia	3/6	2/6	1/6	0/6
-neutropenia	5/6	0/6	1/6	0/6
-thrombo cytopenia	gr 0 all			
GI				
- N/V	3/3	3/3	0/3	0/3
-diarrhea	gr 0 all			
Renal	gr 0 all			
Mucositis	5/6	1/6	0/6	0/6

Comparison during concurrent period

	cisplatin 30 mg/m ²	cisplatin 100 mg/m ²
compliance	2/2	8/9
Toxicity(gr3/4) - neutropenia - mucositis	0/2 in week 5 th	1/9 in week 5 th

Thank you